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Abstract
Background and Aim: The first genome-wide association study on birth weight was recently published and the most
significant associated birth weight lowering variant was the rs900400 C-allele located near LEKR1 and CCNL1. We aimed to
replicate the association with birth weight in the Danish Inter99 study and furthermore to evaluate associations between
rs900400 and indices of insulin secretion and insulin sensitivity obtained by oral glucose tolerance tests in adults from the
Danish Inter99 study and the Finnish, Metabolic Syndrome in Men (METSIM) sample.
Methods: For 4,744 of 6,784 Inter99 participants, midwife journals were traced through the Danish State Archives and
association of rs900400 with birth weight was examined. Associations between rs900400 and fasting serum insulin, fasting
plasma glucose, insulinogenic index, homeostasis model assessment of insulin resistance (HOMA-IR) and disposition index
were studied in 5,484 Danish and 6,915 Finnish non-diabetic individuals and combined in meta-analyses.
Results: The C-allele of rs900400 was associated with a 22.1 g lower birth weight ([241.3;23.0], P=0.024) per allele.
Moreover, in combined analyses of the Danish Inter99 study and the Finnish METSIM study we found that the birth weight
lowering allele was associated with increased insulin release measured by the insulinogenic index (b=2.25% [0.59; 3.91],
P=0.008) and with an increased disposition index (b=1.76% [0.04; 3.49], P=0.05).
Conclusion: The birth weight lowering effect of the C-allele of rs900400 located near LEKR1 and CCNL1 was replicated in the
Danish population. Furthermore the C-allele was associated with increased insulin response following oral glucose
stimulation in a meta-analysis based on Danish and Finnish non-diabetic individuals.
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Introduction
Birth weight is a crude measure of the entire period of pre-natal
growth. It is a complex trait influenced by multiple intrauterine
factors as well as the genetic disposition of both the fetus and the
mother. It is well known that low birth weight is associated with
adult-onset metabolic diseases including type 2 diabetes (T2D)
[1,2] and it has been hypothesized that this link is due to foetal
growth restriction being detrimental for the natural organ
development [3]. Besides, recent data provided proof-of-concept
for the idea that the relationship between low birth weight and risk
of T2D to some extent may be explained by common genetic
disposition to both traits (the fetal insulin hypothesis) [4]. This
hypothesis is based on insulin being an important fetal growth
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action may result in both reduced fetal growth and risk of T2D.
Thus, lower birth weight was found among carriers of T2D risk
alleles in or near HHEX-IDE, CDKAL1 and ADCY5 [5,6,7,8,9],
however only the latter was confirmed at genome-wide signifi-
cance. Risk alleles in HHEX-IDE and CDKAL1 confer increased
risk of T2D due to lower insulin secretion [10,11] and the birth
weight lowering effect of these two alleles suggests that insulin
secretion is diminished already in pre-natal life. This may as well
be the case for the ADCY5 risk allele, but the exact mechanism by
which this variant predisposes to both low birth weight and T2D is
yet to be determined [12]. However, several T2D risk alleles
affecting adult insulin secretion have not been found to have an
effect on birth weight. Variants in the FTO and TCF7L2 loci have
been tested in large cohorts [13,14], but it cannot be excluded that
for other variants the lack of association with birth weight might be
due to missing power.
The first genome-wide association (GWA) study on birth weight
demonstrated that rs9883204 located in ADCY5 and rs900400 located
near LEKR1 and CCNL1 were associated with a decrease in birth
weight by 0.063 and 0.086 z-score units per allele, respectively [5].
By investigating published GWA-databases from the GIANT
and MAGIC consortia the authors found that, while the ADCY5
locus was related to T2D, rs900400 was not associated with either
T2D, height, BMI, or fasting glyceamic traits [5]. So far, genetic
variants in or near LEKR1 and CCNL1 have not been reported to
be associated with adult metabolic phenotypes. Due to limited
knowledge about this novel signal, we aimed to confirm the
association between rs900400 and birth weight in the Danish
population and furthermore to evaluate associations between
rs900400 and five indices of insulin release and insulin sensitivity
obtained from an oral glucose tolerance test in adults of the Danish
Inter99 population and the Finnish Metabolic Syndrome in Men
(METSIM) study as well as in combined analyses.
Materials and Methods
Study population
Inter99. Ethics statement: All participants gave written
informed consent and the protocol was in accordance with the
Helsinki Declaration, and approved by Copenhagen County ethic
committee (ClinicalTrials.gov NCT00289237).
Individuals examined in the present study were from the Danish
Inter99 study, which at baseline comprised 6,784 individuals living
in the region of Copenhagen. The Inter99 study is a population-
based, randomised non-pharmacological intervention study of
prevention of ischemic heart disease conducted at the Research
Centre for Prevention and Health in Glostrup, Denmark (www.
inter99.dk) [15,16]. For 4,744 participants, midwife journals were
traced through the Danish State Archives. These journals
contained information on mother’s age, parity and marital status
as well as birth weight, length at birth and prematurity of the
newborn [17]. Ponderal index was calculated as birth weight (kg) /
birth length (m)
3. Birth weight characteristics of participants
included in the study can be seen in Table 1. Information about
maternal diabetes status (yes/no/unknown) was obtained by a
questionnaire during the baseline visit in 1999–2001. The age of
onset of maternal diabetes was not registered. Term birth was
defined by a gestational week between 37 and 41. Preterm
singleton deliveries (n=446) and individuals born from multiple
pregnancies (n=85) were excluded. The final number of
individuals included in the analyses of birth weight was 4,210.
Association between the rs900400 genotype and quantitative
diabetes-related traits were studied in 5,484 non-diabetic individ-
uals from the population-based Inter99 sample of Danish
individuals aged 30–60 years. All participants had an oral glucose
tolerance test (OGTT). Included in the analysis were 4,329
individuals with normal glucose tolerance (NGT), 489 individuals
with impaired fasting glycaemia (IFG) and 666 individuals with
impaired glucose tolerance (IGT). Patients in the Inter99 sample
with diabetes were not included in the present analysis of
quantitative traits. All individuals were Danes by self report.
METSIM. Ethics statement: Written informed consent has been
obtained from each participant after the purpose and the risks/benefits
of the study have been explained. The study was approved by the
Ethics Committee of the University of Kuopio and Kuopio University
Hospital, and it was in accordance with the Helsinki Declaration.
Individuals from the population-based cross-sectional Metabolic
Syndrome in Men (METSIM) study comprise 10,197 men aged 45
to 70 years. The men have been randomly selected from the
population register of the town of Kuopio in eastern Finland
(population 95,000). Every participant had a 1-day outpatient visit
to the Clinical Research Unit at the University of Kuopio,
including an interview on the history of previous diseases and
current drug treatment and an evaluation of glucose tolerance and
cardiovascular risk factors. No birth weight data were available for
the participants. Associations between the rs900400 genotype and
quantitative diabetes related traits were studied in 6,915 non-
diabetic individuals. Of these participants, 4,638 had normal
glucose tolerance, 1,206 isolated impaired fasting glucose (IFG),
630 isolated impaired glucose tolerance (IGT), 441 a combination
of IFG and IGT according to WHO 1997 criteria [18].
Biochemical measures
Inter99. Blood samples were drawn after an overnight fast
followed by an OGTT. Plasma glucose was analyzed by a glucose
oxidase method (Granutest; Merck, Darmstadt, Germany). Serum
insulin ((excluding des-31,32) and intact proinsulin) was measured
using the AutoDELFIA insulin kit (Perkin-Elmer, Wallac, Turku,
Finland).
METSIM. Blood samples were drawn after 12 h of fasting
followed by an OGTT. Plasma glucose was measured from plasma
(FC-mixture: NaF/ Na-Citrate/ EDTA-Na2) by Enzymatic
photometric test, Glucose hexokinase. Reagent: Konelab System
Table 1. Birth weight characteristics of participants from the
Inter99 study and characteristics of non-diabetic participants
from the Inter99 study and from the METSIM study.
Inter99 N Inter99 N METSIM
Years of birth 1939–1970
Birth weight (g) 4210 34886450
Birth lenght (cm) 4197 5262
Ponderal index 4197 24.862.3
Age (years) 5484 46.067.9 6915 57.167.0
Body mass index (kg/m
2) 5483 26.064.4 6912 26.863.8
Fasting insulin (pmol/l) 5292 40.6626.1 6911 49.1634.0
Fasting plasma glucose (mmol/l) 5479 5.560.5 6915 5.760.5
HOMA-IR (mmol/l*pmol/l) 5290 1.761.1 6911 2.161.5
Insulinogenic index
(pmol/l / mmol/l)
5040 29.8619.6 6876 39.9630.1
Disposition index 5040 22.6616.8 6876 22.6616.0
Data are mean 6 standard deviation or median (interquartile range).
doi:10.1371/journal.pone.0027096.t001
rs900400 Associates with Elevated Insulin Release
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Finland. Instrumentation: Konelab 20XTi Clinical Chemistry
Analyzer, Thermo Fisher Scientific, Vantaa, Finland. Insulin was
measured in mU/l units (converted to pmol/l multiplying
by 6) from plasma (EDTA) by Immunoassay, luminometric
measurement. Reagent: ADVIA Centaur Insulin IRI, no
02230141, Siemens Medical Solutions Diagnostics, Tarrytown,
NY, USA. Instrumentation: Siemens ADVIA CentaurH, Siemens
Medical Solutions Diagnostics, Tarrytown, NY, USA.
Indices of insulin release and insulin sensitivity for both
study samples. Oral glucose-stimulated insulin release was
reported as the insulinogenic index. The insulinogenic index was
calculated as (serum insulin at 30 minutes [pmol/l]-fasting serum
insulin [pmol/l]) / plasma glucose at 30 minutes (mmol/l).
Homeostasis model assessment of insulin resistance (HOMA-IR)
was calculated as ((fasting plasma glucose (mmol/l) * fasting serum
insulin (pmol/l)) / 135) for the Inter99 cohort and as ((fasting
plasma glucose (mmol/l) * fasting plasma insulin (mU/l))/ 22.5) in
the METSIM cohort. In order to construct an OGTT-based
disposition index, we divided insulinogenic index with the
reciprocal of HOMA-IR (Insulinogenic index/HOMA-IR).
Clinical characteristics of the Inter99 and METSIM individuals
are shown in Table 1.
Genotyping
Inter99. Genotyping was performed using KASParH
genotyping (KBioscience, Hoddesdon) with a success rate of
98.3% and an error rate of 0% in 454 duplicate samples. There
was a slight deviation from Hardy Weinberg equilibrium
(P=0.011).
METSIM. Genotyping was performed using the Applied
Biosystems TaqMan Allelic Discrimination Assay with a success
rate of 98.1% and an error rate of 0% in 4.5% duplicate samples.
The genotype distribution was consistent with Hardy Weinberg
equilibrium (P=1.0).
Statistical analysis
Inter99. All statistical analyses were performed using RGui
version 2.8.1 (available at http://www.r-project.org). The
associations of rs900400 with birth weight, length at birth and
ponderal index in the Inter99 population were calculated using
linear regression models adjusted for sex, maternal diabetes (yes vs.
no/NA) and parity (0, 1, 2, 3 or $4). Z-scores were calculated as
[value-mean]/standard deviation (based on the mean and SD
birth weight in the included Inter99 sample).
METSIM. Statistical analyses were performed using SPSS
version 17 (SPSS, Chicago, IL). Associations with quantitative
variables during an OGTT were performed as described below.
Both studies. Associations of rs900400 with indices of insulin
release and insulin sensitivity were performed by linear regression
models adjusted for age or for age and BMI (the analyses were also
adjusted for sex in the Inter99 sample). Effect sizes are given as
actual values or percentage (%) if the trait was natural
logarithmically (ln) transformed. Only additive genetic models
were considered assuming a constant change per risk allele and a
P-value ,0.05 was considered significant.
Fixed effect meta-analyses (up to n=12,394) were performed using
effect size estimates and standard errors (SE) derived from linear
regressionanalysesfromtheInter99(adjustedforageandsex)and the
METSIM (adjusted for age) populations. The weight of the two
studies in the meta-analyses was estimated using inverse variance
assuming fixed effects. Heterogeneity was measured by Q-statistics.
Statistical power was estimated using 1000 simulations. We used
the empirical variance of the observed traits in the Danish Inter99
cohort to simulate phenotypes from a normal distribution, so that
variance across genotypes is drawn from the estimated variance.
In the combined analyses, we have estimated the effect sizes that
we have more than 80% statistical power to detect (P,0.05)
assuming a minor allele frequency of 40% resembling the
HapMap-CEU frequency of rs900400 (Table S1).
Results
In 4,210 individuals from the Danish Inter99 population the C-
allele of rs900400 near LEKR1 and CCNL1 was associated with
22.1 g lower birth weight per allele (95% CI 241.3;23.0,
P=0.024). A trend towards a lower ponderal index was also
observed (b=20.08 [20.18;0.01], P=0.094) for carriers of the C-
allele, whereas length at birth was not associated with rs900400
(P=0.230) (Table 2).
In the Inter99 study, we found that the birth weight lowering C-
allele was associated with increased insulin release as estimated by
the insulinogenic index (b=3.3% [1.0;5.6], P=0.005) as well as
increased disposition index (b=3.6% [1.0;6.2], P=0.007)
(Table 3). Moreover, we found a lower fasting plasma glucose
level (20.02 mmol/l [20.04;20.002], P=0.021) for carriers of
the birth weight lowering allele in the Inter99 cohort. These
observations, except the findings for fasting plasma glucose, were
also observed in the subgroup of individuals with normal glucose
tolerance in Inter99 (data not shown). The C-allele of rs900400
was not significantly associated with any of the five traits in the
METSIM population (table 3). However, the directions of the
associations with insulinogenic index and disposition index were
similar to what was observed in the Inter99 sample although the
effect size estimates were considerably smaller in the METSIM
population. Additional adjustment for BMI in all analyses did not
Table 2. Associations between rs900400 near LEKR1 and CCNL1 and birth weight, birth length and ponderal index in the Danish
Inter99 sample.
TT TC CC Effect Effect z-score P
N 1332 1875 722
(Men/Women) (640/692) (893/982) (326/396)
Birth weight (g) 34936451 35036446 34356439 222.1[241.3;23.0] 20.05[20.09;20.01] 0.024
Birth length (cm) 52625 2 625 2 62 20.05[20.13;0.03] 20.03[20.07; 0.02] 0.23
Ponderal index (kg/m
3) 24.862.3 24.862.3 24.662.2 20.08[20.18;0.01] 20.04[20.08;0.01] 0.094
Effects and P-values are adjusted for sex, maternal diabetes and parity assuming an additive model of inheritance. Ponderal index was calculated as birth weight (kg)/
birth length (m)
3.
doi:10.1371/journal.pone.0027096.t002
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from the Inter99 and METSIM studies were performed for all five
metabolic traits (fasting serum insulin, fasting plasma glucose,
insulinogenic index, HOMA-IR and disposition index) including
up to 12,394 individuals. In combined meta-analyses the C-allele
of rs900400 was associated with increased insulin response to an
oral glucose load estimated by the insulinogenic index (b=2.25%
[0.59; 3.91], P=0.008, figure 1 and table 4) and with an increased
Table 3. Associations between rs900400 near LEKR1 and CCNL1 and quantitative metabolic traits during an oral glucose tolerance
test in 5,484 non-diabetic participants of the Inter99 study and 6,915 non-diabetic men from the METSIM study.
Inter99 TT TC CC Effect [95% CI] P
N (Men/Women) 1908(926/982) 2584(1297/1287) 992(463/529)
Age (years) 46684 6 684 5 68
Fasting serum insulin (pmol/l) 40.91626.05 40.09626.16 41.05626.09 20.3% [22.4;1.9] 0.81
Fasting plasma glucose (mmol/l) 5.4760.51 5.4660.51 5.4160.52 20.02 mmol/l [20.04;0.0] 0.021
HOMA-IR (mU/l * mmol/l) 1.6861.13 1.6561.14 1.6761.12 20.6% [22.9;1.7] 0.62
Insulinogenic index (pmol/l / mmol/l) 29.07618.26 29.51619.36 31.69622.14 3.3% [1.0;5.6] 0.005
Disposition index (Insulinogenic index / HOMA-IR) 21.91615.92 22.5616.32 23.89619.23 3.6% [1.0;6.2] 0.007
METSIM TT TC CC Effect [95% CI] P
N 3331 2934 647
Age (years) 57.066.9 57.167.0 57.567.0
Fasting plasma insulin (pmol/l) 48.88633.51 49.19634.44 50.04634.61 0.9% [21.2;3.0] 0.419
Fasting plasma glucose (mmol/l) 5.7060.48 5.7160.49 5.7060.47 0.00 mmol/l [20.02;0.02] 0.982
HOMA-IR (mU/l *mmol/l) 2.1061.53 2.1161.55 2.1461.52 0.9% [21.4;3.1] 0.445
Insulinogenic index (pmol/l / mmol/l) 39.55629.53 40.03630.53 40.92630.93 1.2% [21.2;3.5] 0.340
Disposition index (Insulinogenic index / HOMA-IR) 22.56616.25 22.70615.81 22.32615.34 0.2% [22.1;2.4] 0.890
Data are mean6SD and are stratified according to genotype of rs900400. Effects are given as actual values (plasma glucose) or percentage (%) (all other traits) since
these traits are logarithmically transformed. Effects and p-values are adjusted for age (and sex in Inter99) assuming an additive model of inheritance.
doi:10.1371/journal.pone.0027096.t003
Figure 1. Meta-analysis of rs900400 and insulinogenic index including 11,916 individuals from the Inter99 and METSIM study. Effect
size estimates and standard errors are combined in a meta-analysis using the inverse variance method. The black diamond represents the combined
change in insulinogenic index per C-allele. Effect size estimate (b) and P-value are presented for the combined analysis with 95% confidence interval
in square brackets.
doi:10.1371/journal.pone.0027096.g001
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P=0.05, table 4). No other traits were associated with rs900400 in
the meta-analyses (table 4). No heterogeneity was observed in any
of the meta-analyses (P.0.05).
Discussion
We confirm the association of rs900400 C-allele near LEKR1 and
CCNL1 with lower birth weight in the Danish Inter99 study sample.
The same allele was found by Freathy et al. to be associated with a
lower ponderal index in 21,515 European individuals [5]. We also
observe a trend towards a lower ponderal index, although this trait
does not reach statistical significance in our cohort.
Our confidence interval is just overlapping with the estimated
effect size reported by Freathy et al, indicating that statistically the
effect sizes are similar in the two cohorts. However, the effect size
estimates of birth weight and ponderal index in the present study
are slightly lower than the combined effects reported by Freathy
et al [5]. This could be explained by general population differences
and slight deviations in linkage equilibrium among the popula-
tions, assuming that this polymorphism is not the causative
variant. Moreover, we were not able to adjust for gestational age
also impeding the accuracy of birth weight as a measure of growth
conditions. However, in the GWA meta-analysis three studies
without information about gestational age did not introduce
heterogeneity in the overall analyses suggesting that this variant is
not strongly associated with gestational age [5].
Surprisingly, in meta-analyses based on the Danish Inter99 and
Finnish METSIM studies we found an increased oral glucose
stimulated insulin release measured by the insulinogenic index and
the disposition index in carriers of the birth weight lowering C-allele.
The disposition index could be considered as an estimate of the
ability of the pancreatic beta cells to respond appropriately to the
level of insulin sensitivity. If these data are upheld in larger study
samples, it can be suggested that the increased insulin release
represents a primary metabolic feature in these individuals. This
finding may appear in contrast to what may have been expected
according to the fetal insulin hypothesis [4] and based on recent
observations for birth weight lowering variants in or near CDKAL1,
HHEX-IDE and ADCY5 [5–9]. Nevertheless, the variant near
LEKR1 and CCNL1 was not associated with impaired b-cell function
or insulin action demonstrating that genetic variants conferring low
birth weight may not necessarily be related to an adverse glycemic
phenotype.Adultdeterminantsofinsulinsecretionandinsulinaction
may however not reflect insulin regulation in fetal life. In this study
the adult insulin secretion was measured as a response to an oral
glucose challenge, which triggers insulin secretion through the gut
and not through the umbilical cord like inthe uterus. It could also be
speculated that the increased secretion may somehow be related to
compensatory post-natal mechanisms. Furthermore, ithas been seen
before that a mutation can cause opposite effects on insulin secretion
in early versus later life, since a HNF4A mutation causes
hyperinsulimea in utero and then later causes diabetes in adulthood
[19]. Obviously further genetic epidemiological and metabolic
studies in representative study samples are needed to verify the
findings. In order to achieve genome-wide significance with 80%
statistical power, sample sizes of .56,000 individuals are needed.
In our study, associations to five metabolic traits have been
examined. Although some traits are correlated, we recognize the
possibility of the associations being false positive findings due to
lack of correction for multiple testing. However, if a stringent
Bonferroni correction for five independent tests were performed,
the association with the insulinogenic index observed in the
combined analysis still remains statistically significant.
In conclusion, we confirm the association with lower birth weight
for the C-allele of rs900400 located near LEKR1 and CCNL1 and we
demonstrate a novel association with increased insulin response for
carriers of the birth weight lowering allele. The validity of the
present findings needs to be tested in future studies.
Supporting Information
Table S1 Effect sizes that we have 80% statistical power to
detect in the combined analyses with a minor allele frequency of
40% and with a P-value of 0.05 for the five listed traits.
(DOC)
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